C0288800-Cancer_cell_and_T_lymphocytes_SEM
STEVE GSCHMEISSNER/SCIENCE PHOTO LIBRARY
The effort to make a breakthrough cancer therapy cheaper
CAR-T therapies, created by engineering a patient’s own cells to fight cancer, are typically reserved for people who have exhausted other treatment options. But last week, the FDA approved Carvykti, a CAR-T product for multiple myeloma, as a second-line therapy. That means people are eligible to receive Carvykti after their first relapse.
